JP2025041724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025041724A5 JP2025041724A5 JP2024221343A JP2024221343A JP2025041724A5 JP 2025041724 A5 JP2025041724 A5 JP 2025041724A5 JP 2024221343 A JP2024221343 A JP 2024221343A JP 2024221343 A JP2024221343 A JP 2024221343A JP 2025041724 A5 JP2025041724 A5 JP 2025041724A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- pharmaceutical composition
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9 | 2019-05-21 | ||
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
| JP2021569042A JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Division JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025041724A JP2025041724A (ja) | 2025-03-26 |
| JP2025041724A5 true JP2025041724A5 (enExample) | 2025-05-26 |
Family
ID=67385155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Active JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024221343A Pending JP2025041724A (ja) | 2019-05-21 | 2024-12-18 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569042A Active JP7607590B2 (ja) | 2019-05-21 | 2020-05-21 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
| JP2024220534A Pending JP2025038109A (ja) | 2019-05-21 | 2024-12-17 | 異常タンパク質性ニューロパチーを治療する方法において使用するための補体系のアンタゴニスト |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20250066460A1 (enExample) |
| EP (2) | EP3972643B1 (enExample) |
| JP (3) | JP7607590B2 (enExample) |
| KR (1) | KR20220010505A (enExample) |
| CN (2) | CN118021970A (enExample) |
| AU (1) | AU2020279543A1 (enExample) |
| BR (1) | BR112021023198A2 (enExample) |
| CA (1) | CA3138401A1 (enExample) |
| DK (1) | DK3972643T3 (enExample) |
| EA (1) | EA202193189A1 (enExample) |
| ES (1) | ES3035736T3 (enExample) |
| FI (1) | FI3972643T3 (enExample) |
| GB (1) | GB2584105B (enExample) |
| HU (1) | HUE072743T2 (enExample) |
| IL (1) | IL288010A (enExample) |
| LT (1) | LT3972643T (enExample) |
| MA (1) | MA71752A (enExample) |
| MX (2) | MX2021014170A (enExample) |
| PL (1) | PL3972643T3 (enExample) |
| PT (1) | PT3972643T (enExample) |
| SG (1) | SG11202112232YA (enExample) |
| WO (1) | WO2020234432A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| WO2022198108A1 (en) * | 2021-03-18 | 2022-09-22 | Affilogic | Polypeptides for complement inhibition |
| US20250074973A1 (en) * | 2021-12-30 | 2025-03-06 | Annexon, Inc. | Compositions and methods for treating huntington’s disease |
| CA3259060A1 (en) * | 2022-07-14 | 2024-01-18 | argenx BV | DOSAGE REGIMEN FOR THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY (MMN) |
| KR20250158059A (ko) * | 2023-03-07 | 2025-11-05 | 더 클리브랜드 클리닉 파운데이션 | 인간 보체 성분 2 결합 분자 |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| KR101503540B1 (ko) * | 2006-09-05 | 2015-03-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항체 매개된 신경병증의 치료를 위한 방법과 조성물 |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| SI3028716T1 (sl) * | 2006-10-10 | 2021-01-29 | Regenesance B.V. | Komplementarna inhibicija za izboljšano regeneracijo živcev |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| CA2847862C (en) * | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| WO2014186622A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| US9944717B2 (en) * | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| CA2931090A1 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| ES3013108T3 (en) * | 2014-11-05 | 2025-04-11 | Annexon Inc | Humanized anti-complement factor c1q antibodies and uses thereof |
| US11091591B2 (en) * | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| CN115260310B (zh) * | 2015-11-24 | 2025-02-25 | 安尼艾克松股份有限公司 | 抗补体因子c1q的fab片段及其应用 |
| EP3454902A4 (en) * | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| BR112019018950A2 (pt) * | 2017-03-14 | 2020-04-22 | Bioverativ Usa Inc. | métodos para tratamento de doenças e distúrbios mediados por complemento |
| US11866701B2 (en) * | 2017-11-01 | 2024-01-09 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| LT3893924T (lt) * | 2018-12-13 | 2024-10-10 | argenx BV | Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 US US17/608,637 patent/US20250066460A1/en active Pending
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 AU AU2020279543A patent/AU2020279543A1/en active Pending
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7071349B2 (ja) | ピログルタメートアミロイド－βに対する抗体及びその使用 | |
| FI3972643T3 (fi) | Komplementtijärjestelmän antagonisteja käytettäväksi paraproteinemisten neuropatioiden hoitomenetelmissä | |
| JP2023515271A5 (enExample) | ||
| IL276695A (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| JP2025131696A5 (enExample) | ||
| JP2020522513A5 (enExample) | ||
| NZ568403A (en) | CD20-specific antibodies and methods of employing same | |
| JP2015514110A5 (enExample) | ||
| JP2003528052A5 (enExample) | ||
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| RU2012141556A (ru) | Способы и композиции для лечения болезни дего | |
| RU2011117237A (ru) | АНТИТЕЛА ПРОТИВ Notch2 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2010132956A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
| JP2015503909A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| JP2025067915A5 (enExample) | ||
| JP2022533705A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| JP2023506465A5 (enExample) | ||
| JP2021511387A5 (enExample) | ||
| JP2022543658A5 (enExample) | ||
| JP2020500005A5 (enExample) | ||
| JP2025503400A5 (enExample) | ||
| PT2432804E (pt) | Anticorpos ou seus fragmentos direcionados contra um epítopo de staphylococcus aureus de isaa ou isab |